N-<4-(2-phthalimido)butyl>-2-phenyl-1-aminoethane | 120991-52-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-<4-(2-phthalimido)butyl>-2-phenyl-1-aminoethane
• 英文别名: 2-(4-Phenethylamino-butyl)-isoindole-1,3-dione；2-[4-(2-phenylethylamino)butyl]isoindole-1,3-dione
• CAS: 120991-52-8
• 化学式: C₂₀H₂₂N₂O₂
• 分子量: 322.407
• InChiKey: STJYUDOHLYFSEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-<4-(2-phthalimido)butyl>-2-phenyl-1-aminoethane 、 一水合肼 在 甲醇 、 Brine 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 8.0h， 以N-benzyl-N-methylbutane-1,4-diamine is obtained的产率得到4-(1-苄基-1-甲基氨基)丁基胺
  参考文献：
  名称：

  Modulators of Chemokine Receptor Activity

  摘要：

  公式为（I）的化合物，其取代基如上所述，在治疗由CCR3作用介导的疾病中有用，特别是炎症或阻塞性气道疾病。

  公开号：

  US20080306067A1
• 作为产物：
  描述：

  N-(4-溴丁基)邻苯二甲酰亚胺 、 2-苯乙胺 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以23%的产率得到N-<4-(2-phthalimido)butyl>-2-phenyl-1-aminoethane
  参考文献：
  名称：

  N-(phthalimidoalkyl) derivatives of serotonergic agents: a common interaction at 5-HT1A serotonin binding sites?

  摘要：

  Several classes of agents are known to bind at central 5-HT1A serotonin sites In order to challenge the hypothesis that these agents bind in a relatively similar manner (i.e., share common aryl and terminal amine sites), we prepared N-(phthalimidobutyl) derivatives of examples of several such agents. With regard to arylpiperazines, we had previously shown that introduction of this functionality at the terminal amine is tolerated by the receptor and normally results in a significant (greater than 10-fold) enhancement in affinity. The results of the present study show that this bulky functionality is also tolerated by the receptor when incorporated into examples of all other major classes of 5-HT1A agents (e.g., 2-aminotetralin, phenylalklamine, indolylalkylamine, and (aryloxy)alkylamine derivatives). The length of the alkyl chain that separates the terminal amine from the phthalimido group is of major importance, and a four-carbon chain appears optimal. Alteration of the length of this chain can have a significant influence on affinity; decreasing the chain length from four to three carbon atoms can reduce affinity by an order of magnitude, and further shortening can have an even more pronounced effect.

  DOI：

  10.1021/jm00128a039

文献信息

• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LILLE II DROIT & SANTE

  公开号：WO2015193255A1

  公开（公告）日：2015-12-23

  The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

  本发明涉及公式（I）的新化合物，以及其药用盐或溶剂和它们的用途。
• Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
  申请人：UNIVERSITE DE LILLE 2 DROIT ET SANTE

  公开号：US10179761B2

  公开（公告）日：2019-01-15

  The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

  本发明涉及新型式 (I) 化合物、其药学上可接受的盐或溶液及其用途。
• GLENNON, RICHARD A.;NAIMAN, NOREEN A.;PIERSON, M. EDWARD;SMITH, J. DOYLE;+, J. MED. CHEM., 32,(1989) N, C. 1921-1926
  作者：GLENNON, RICHARD A.、NAIMAN, NOREEN A.、PIERSON, M. EDWARD、SMITH, J. DOYLE、+

  DOI：——

  日期：——
• ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Novartis AG

  公开号：EP1943235A1

  公开（公告）日：2008-07-16
• COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES
  申请人：Université de Lille 2 Droit et Santé

  公开号：EP3154934A1

  公开（公告）日：2017-04-19